Hemoglobin β Expression Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma.
hemoglobin β-chain (HBB)
malignant transformation
redox balance
renal cell carcinoma (RCC)
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
30 Apr 2023
30 Apr 2023
Historique:
received:
27
03
2023
revised:
24
04
2023
accepted:
28
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
The regulation of the redox balance in the tumor microenvironment is thought to be an adaptive response of tumor cells to hypoxic environments. In recent years, it has been reported that the hemoglobin β-chain (HBB), which is involved in scavenging reactive oxygen species (ROS), is expressed in several carcinomas. However, the relationship between HBB expression and the prognosis of renal cell carcinoma (RCC) remains unclear. HBB expression was immunohistochemically analyzed in 203 nonmetastatic clear cell RCC (ccRCC) cases. Cell proliferation, invasion, and ROS production were measured in ccRCC cell lines treated with HBB-specific siRNA. The prognosis of HBB-positive patients was worse than that of HBB-negative patients. Cell proliferation and invasion were inhibited, and ROS production was increased by treatment with HBB-specific siRNA. Oxidative stress increased HBB expression in cells exposed to H HBB expression in ccRCC contributes to cancer cell proliferation by suppressing ROS production under hypoxic conditions. Taken together with clinical results and in vitro experiments, HBB expression may serve as a new prognostic biomarker for RCC in the future.
Sections du résumé
BACKGROUND
BACKGROUND
The regulation of the redox balance in the tumor microenvironment is thought to be an adaptive response of tumor cells to hypoxic environments. In recent years, it has been reported that the hemoglobin β-chain (HBB), which is involved in scavenging reactive oxygen species (ROS), is expressed in several carcinomas. However, the relationship between HBB expression and the prognosis of renal cell carcinoma (RCC) remains unclear.
METHODS
METHODS
HBB expression was immunohistochemically analyzed in 203 nonmetastatic clear cell RCC (ccRCC) cases. Cell proliferation, invasion, and ROS production were measured in ccRCC cell lines treated with HBB-specific siRNA.
RESULTS
RESULTS
The prognosis of HBB-positive patients was worse than that of HBB-negative patients. Cell proliferation and invasion were inhibited, and ROS production was increased by treatment with HBB-specific siRNA. Oxidative stress increased HBB expression in cells exposed to H
CONCLUSIONS
CONCLUSIONS
HBB expression in ccRCC contributes to cancer cell proliferation by suppressing ROS production under hypoxic conditions. Taken together with clinical results and in vitro experiments, HBB expression may serve as a new prognostic biomarker for RCC in the future.
Identifiants
pubmed: 37239002
pii: biomedicines11051330
doi: 10.3390/biomedicines11051330
pmc: PMC10216096
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Grant-in-Aid for Scientific Research
ID : 20K09554
Références
Br J Cancer. 2005 Jun 20;92(12):2216-24
pubmed: 15956966
Am J Respir Cell Mol Biol. 2011 Apr;44(4):439-47
pubmed: 20508070
PLoS One. 2011;6(9):e24363
pubmed: 21931690
Biochim Biophys Acta. 2013 Sep;1834(9):1939-43
pubmed: 23685348
Hum Reprod. 2008 Mar;23(3):635-41
pubmed: 18216035
Biochim Biophys Acta. 2003 Jan 20;1637(1):46-54
pubmed: 12527406
J Am Soc Nephrol. 2008 Aug;19(8):1500-8
pubmed: 18448584
Cancer Treat Rev. 2008 May;34(3):193-205
pubmed: 18313224
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Nat Genet. 2013 Aug;45(8):860-7
pubmed: 23797736
Nature. 2009 Sep 3;461(7260):109-13
pubmed: 19693011
Nat Commun. 2017 Feb 09;8:14344
pubmed: 28181495
J Clin Oncol. 2014 Dec 20;32(36):4059-65
pubmed: 25403213
Cancer Cell. 2018 Jun 11;33(6):985-1003.e7
pubmed: 29805077
Int J Inflam. 2014;2014:803237
pubmed: 25431740
Br J Cancer. 2017 Sep 26;117(7):994-1006
pubmed: 28772282
J Cereb Blood Flow Metab. 2009 Mar;29(3):585-95
pubmed: 19116637
Cancer Sci. 2023 Feb;114(2):436-448
pubmed: 36178067
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
Oncotarget. 2019 Jun 18;10(40):4053-4068
pubmed: 31258849
Cell. 2019 Jul 11;178(2):316-329.e18
pubmed: 31257023
J Biol Chem. 1996 Apr 26;271(17):10130-6
pubmed: 8626572
J Cell Biol. 2011 Jul 11;194(1):7-15
pubmed: 21746850
Curr Biol. 2014 May 19;24(10):R453-62
pubmed: 24845678
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
FEBS J. 2022 Sep;289(18):5413-5425
pubmed: 34228878
Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15454-9
pubmed: 19717439
Cancer Cell. 2015 Feb 9;27(2):211-22
pubmed: 25620030
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9926-30
pubmed: 7937919
Cancer Treat Rev. 2016 Nov;50:109-117
pubmed: 27664394
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Cell. 2019 Jul 11;178(2):330-345.e22
pubmed: 31257027
Nat Rev Cancer. 2022 May;22(5):280-297
pubmed: 35102280
Nature. 2015 Nov 12;527(7577):186-91
pubmed: 26466563
Int J Urol. 2015 Sep;22(9):S1-7
pubmed: 26332059
Int J Mol Sci. 2022 Jul 30;23(15):
pubmed: 35955582
J Biol Chem. 2006 Mar 3;281(9):5668-76
pubmed: 16407281
Cancer Res. 2017 Jan 1;77(1):14-26
pubmed: 27793844
J Cancer Res Clin Oncol. 2023 Jan;149(1):79-90
pubmed: 36374334
PLoS One. 2013;8(1):e54342
pubmed: 23349856
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1911-9
pubmed: 19060278
Biochem Biophys Res Commun. 2005 Aug 12;333(4):1348-52
pubmed: 15979582